Castle Biosciences expects FY 2021 revenue to meet or exceed $89-93M guidance; test volumes up 55%

CASTLE BIOSCIENCES INC

2021-FY EPS reported -$1.24 revenue$94,085,000

FY2021 revenue expected at or above guided $89-93M; year-end cash ~$330M.
Total gene expression profile test reports delivered in 2021: 28,118 (+55% YoY).
DecisionDx-Melanoma reports up 25% YoY to 20,328 despite 11% drop in melanoma diagnoses vs pre-COVID.
DecisionDx-SCC reports grew to 3,510 in 2021 from 485 in 2020; Q4 2021: 1,265 (+196%).
myPath/DecisionDx DiffDx-Melanoma reports: 2,662 in 2021 vs 73 in 2020; Q4: 904 vs 73.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.